XML 59 R49.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Information            
Interest income $ 191,395   $ 25,978   $ 379,007 $ 70,146
Net loss (6,220,058) $ (5,537,069) (5,020,412) $ (1,066,947) (11,757,127) (6,087,359)
Single reportable segment            
Segment Information            
Program expenses related to clinical-stage product candidates (4,228,642)   (4,676,084)   (8,445,857) (10,588,112)
Program expenses related to preclinical and discovery programs (49,714)   (169,176)   (80,313) (277,514)
Personnel-related expenses (including stock-based compensation) (1,496,642)   (2,333,028)   (2,894,516) (3,527,715)
General and administrative professional and consultant fees (292,649)   (389,485)   (737,514) (758,838)
Other segment items (203,806)   (194,865)   (395,934) (420,266)
Interest income 191,395   25,978   379,007 70,146
Other non-cash income (expense) items (140,000)   2,716,248   418,000 9,414,940
Net loss $ (6,220,058)   $ (5,020,412)   $ (11,757,127) $ (6,087,359)